Southern New Pharmaceutical (688189.SH) plans to acquire the assets held by Future Medicine for no more than 480 million yuan to enrich the company's product pipeline.

Zhtng Cijng APP news, Nanxin Pharmaceuticals (688189.SH) announced that the company has signed a "Acquisition Intention Agreement" with Tibet Future Biopharmaceutical Co., Ltd., Xuchang Future Pharmaceutical Co., Ltd., and Hefei Future Drug Development Co., Ltd. (referred to as "Future Medicine"). The company plans to acquire the target assets held by Future Medicine for no more than 480 million yuan in cash, including the listed target varieties "Multiple Trace Elements Injection (I)", "Multiple Trace Elements Injection (II)", and the research and development target variety "Multiple Trace Elements Injection (III)", as well as the complete ownership and intellectual property rights of assets related to the target varieties, including research and development and production technologies, trademarks, patents, customer data (market channels), approvals, etc. ("This transaction").